Currently, clinically approved PD-L1 testing and corresponding treatments are primarily targeted at TNBC patients in breast cancer, while first-line treatments for non-TNBC patients still involve hormone therapy or Her-2 targeted therapy (Emens & Loi, 2023; Prat et al., 2015). Here, ERBB2 is linked to breast cancer.